The earnings are starting to come in, but the real story is about the long term picture, which is shaping up nicely. Look at the potential. Based on the stated $300K/patient/year and 10K patients in the U.S. & EU; that is $3B/year & with 25M shares out, it equates to $120/share in revenue.
@ P/E of 10 = $1,200/share
@ P/E of 10 = $2,400/share
That's if they get the whole available market. If they get just 10% then market value is still at $120-$240/share.
This medicine is for patients who are dying, so it isn't elective like weight loss drugs, or other medications. With a potential of $1,200-$2,400/share in the long term, and $120-$240 in the short term, this is still a compelling buy.